Opioid UseNCT05875857
Patient Utilization of Opioid Destruction Bags in the Post-op Period
A study testing Opioid destruction education in people with Opioid Use and Opioid Use, Unspecified, run by University of Nebraska at 1 site in United States.
Trial summary
This is a study on how patients use and store opioid pain medications at home after surgery and what happens to left over pills when patients are done taking them. Participants will be taught the proper storage and destruction of opioid pain medications, then contacted in 6-8 weeks about pain medication used, stored… Read more about this study
- Who is it for?
- Ages 19 to 100 years
- Conditions the study is for
- Opioid Use, Opioid Use, Unspecified, Patient Empowerment
- What is being tested?
- Opioid destruction education
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 163 participants
- Where
- 1 siteUnited States
- Study dates
- 19 Jun 2023to Jan 2027
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 to 100 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- 19 years of age or older Discharging to home and prescribed opioids at discharge post total knee arthroplasty or total hip arthroplasty
Who cannot join
- Under 19 years of age Opioid medication use prior to surgery Not prescribed an opioid to take after discharge
Trial locations and contacts
1 site in 1 country.
United States1 site
University of Nebraska Medical Center
Omaha, Nebraska, 68198
About this study
This is a study on how patients use and store opioid pain medications at home after surgery and what happens to left over pills when patients are done taking them. Participants will be taught the proper storage and destruction of opioid pain medications, then contacted in 6-8 weeks about pain medication used, stored disposed of.
Read the detailed description
This is a randomized single-center prospective survey study to describe the utilization of opioid destruction bags in the post-operative period. Participants who underwent surgery for Total Knee Arthroplasty (TKA) or Total Hip Arthroplasty (THA) will be eligible for inclusion if discharging to home with an opioid prescription. Eligible participants will be randomized between two groups: 1) Control group will receive current standard of care 2) Intervention group will receive a specialized handout and patient education on the safe storage of opioid medications, importance of opioid destruction, opioid destruction options and medication destruction (Deterra) bag before discharge. Participants will be phoned/emailed six to eight weeks post-surgery to complete a survey. Attempts will be made on three separate days to reach the participant via phone. If email is preferred, three reminders will be sent to complete the survey. If participant is unreachable, they will be considered lost to follow up. Survey questions will be comprised of various question styles, including: yes/no, multiple choice, and free text answers.
- Conditions
- Opioid Use, Opioid Use, Unspecified, Patient Empowerment, Total Knee Arthoplasty, Total Hip Arthroplasty
- Being tested
- Opioid destruction education
- Medical subject headings
- Patient Participation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Opioid destruction educationBehavioural
Intervention group will receive a specialized handout and patient education on the safe storage of opioid medications, importance of opioid destruction, opioid destruction options and medication destruction (Deterra) bag before discharge.
| Study group | Role | What they receive |
|---|---|---|
| Control | No intervention | Control group will receive current standard of care education and surveys at 6-8 weeks post discharge. |
| Intervention | Experimental | Intervention group will receive a specialized handout and patient education on the safe storage of opioid medications, importance of opioid destruction, opioid destruction options and medication destruction (Deterra) bag before discharge. Surveys will be sent to group at 6-8 weeks post discharge. Receives: Behavioral: Opioid destruction education |
What is being measured
The primary outcome is the main question the study is designed to answer.
Opioid destruction
Number of patients who report they did or plan to destroy unused opioids
Measured: Six to Eight weeks post discharge
Secondary outcomes (4)
Patient Education
Number of patients who recall patient education on storage and disposal of opioid medications at discharge
Measured: Six to Eight weeks post discharge
Opioid Storage
Type of opioid storage method used at home
Measured: Six to Eight weeks post discharge
Opioid Destruction Method
Type of opioid destruction method used or plan to use
Measured: Six to Eight weeks post discharge
Leftover Pills
Estimated number of pills leftover after completion of therapy
Measured: Six to Eight weeks post discharge
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 May 2023
- Study start19 Jun 2023
- Primary completion31 Mar 2025
- Study completionJan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Opioid UseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 163 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Nebraska
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Kristin R Daniel, PharmD, Principal investigator, University of Nebraska
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05875857
- Sponsor's protocol ID
- 0277-22-EP
- Status last verified
- Jan 2026
- First submitted
- 4 May 2023
- Last updated
- 29 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No